Smart Weapons Prove Tough to Design

See allHide authors and affiliations

Science  18 Oct 2002:
Vol. 298, Issue 5593, pp. 522-525
DOI: 10.1126/science.298.5593.522

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Data from several clinical trials of Iressa, an experimental drug in a new class of targeted cancer therapies, have been inconsistent, and some have been flatly disappointing. Even so, on 24 September, the U.S. Food and Drug Administration's Oncology Drug Advisory Committee voted 11 to 3 to recommend that the agency approve the drug to treat a common form of lung cancer, known as non-small-cell lung cancer. The agency now has less than 6 months to decide whether to allow Iressa on the market, and the lobbying has been intense.